Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 173.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 908,819 shares of the biotechnology company's stock after acquiring an additional 576,413 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 1.27% of Aclaris Therapeutics worth $2,254,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ACRS. Stonepine Capital Management LLC boosted its holdings in Aclaris Therapeutics by 27.6% during the third quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company's stock worth $2,828,000 after buying an additional 531,427 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Aclaris Therapeutics during the third quarter worth about $1,053,000. Geode Capital Management LLC boosted its holdings in Aclaris Therapeutics by 9.3% during the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company's stock worth $974,000 after buying an additional 72,309 shares in the last quarter. Peapod Lane Capital LLC purchased a new stake in Aclaris Therapeutics during the fourth quarter worth about $1,003,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Aclaris Therapeutics by 113.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock worth $985,000 after buying an additional 211,585 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company's stock.

Remove Ads

Aclaris Therapeutics Stock Up 1.9 %

Shares of NASDAQ:ACRS traded up $0.03 during trading on Friday, reaching $1.60. The stock had a trading volume of 2,614,942 shares, compared to its average volume of 1,163,694. The business has a fifty day moving average price of $2.16 and a 200-day moving average price of $2.20. The stock has a market cap of $172.67 million, a P/E ratio of -3.08 and a beta of 0.48. Aclaris Therapeutics, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $5.17.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ACRS shares. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday. They set an "overweight" rating on the stock. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. HC Wainwright upgraded shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 target price for the company in a research report on Monday, December 23rd. Finally, Scotiabank initiated coverage on shares of Aclaris Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price for the company. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.